(Atorvastatin + fluconazole + minocycline) is under clinical development by GlobeStar Therapeutics and currently in Phase I for Primary Progressive Multiple Sclerosis (PPMS). According to GlobalData, Phase I drugs for Primary Progressive Multiple Sclerosis (PPMS) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Atorvastatin + fluconazole + minocycline)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Atorvastatin + fluconazole + minocycline) overview
GlobeStar Therapeutics overview
GlobeStar Therapeutics is engaged in the development and sale of Liprostin, a peripheral artery disease (PAD) therapy for controlled drug disease for its patients. It also owns patents of OmniCath I and OmniCath II atherectomy catheters. GlobeStar Therapeutics is headquartered in Richland, Washington, the US.
For a complete picture of (Atorvastatin + fluconazole + minocycline)’s drug-specific PTSR and LoA scores, buy the report here.